Drug intelligence / Profile preview

BL-3050

Development stage: Preclinical
Lead developer: BioLineRx
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

**BL-3050** is an investigational biologic protein complex comprising an engineered recombinant paraoxonase 1 enzyme variant complexed with reconstituted high-density lipoprotein containing apolipoprotein A-I and POPC. It was developed as a catalytic bioscavenger for organophosphate pesticide and nerve-agent poisoning and as a potential anti-atherogenic therapy. The engineered PON1 protein was designed to improve reactivity, solubility, stability, and bacterial expression relative to native human PON1; in mouse studies, intravenous BL-3050 showed protection in chlorpyrifos-oxon poisoning and no apparent toxicity after repeated administration. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2785756/))

Other names: BL3050BL-3050BL 3050

Beyond the preview

Go deeper on BL-3050.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BL-3050.

Explore the full profile